Ionis Pharmaceuticals, Inc.
IONS
$43.03
$0.050.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 100.69% | 10.14% | -30.18% | -7.21% | 19.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.69% | 10.14% | -30.18% | -7.21% | 19.55% |
| Cost of Revenue | -2.04% | -6.85% | -3.97% | 1.52% | -2.68% |
| Gross Profit | 23,662.17% | 29.47% | -135.05% | -18.69% | 97.78% |
| SG&A Expenses | 39.18% | 39.85% | 72.67% | -11.88% | 41.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.17% | 3.52% | 8.62% | -1.74% | 4.57% |
| Operating Income | 311.55% | 1.77% | -898.61% | -3.76% | 26.72% |
| Income Before Tax | 286.60% | -2.87% | -3,768.41% | -2.34% | 14.52% |
| Income Tax Expenses | -131.25% | 54.67% | -141.41% | -154.85% | -99.18% |
| Earnings from Continuing Operations | 286.45% | -2.90% | -1,026.51% | 4.70% | 22.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 286.45% | -2.90% | -1,026.51% | 4.70% | 22.31% |
| EBIT | 311.55% | 1.77% | -898.61% | -3.76% | 26.72% |
| EBITDA | 326.46% | 1.56% | -733.19% | -3.99% | 27.53% |
| EPS Basic | 271.01% | 5.66% | -927.06% | 8.09% | 23.83% |
| Normalized Basic EPS | 307.64% | 8.57% | -642.26% | -0.69% | 21.41% |
| EPS Diluted | 254.19% | 5.66% | -927.06% | 8.09% | 23.83% |
| Normalized Diluted EPS | 281.22% | 8.57% | -642.26% | -0.69% | 21.41% |
| Average Basic Shares Outstanding | 9.03% | 9.07% | 9.72% | 3.68% | 2.00% |
| Average Diluted Shares Outstanding | 24.92% | 9.07% | 9.72% | 3.68% | 2.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |